Nurix Therapeutics (NRIX) Interest & Investment Income (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Interest & Investment Income data on file, last reported at $4.4 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 21.72% year-over-year to $4.4 million in Q2 2026; TTM through May 2026 was $19.6 million, a 18.46% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, up 11.36% from the prior year.
• Interest & Investment Income for Q2 2026 stood at $4.4 million, down from $5.3 million in the prior quarter.
• Over the last five years, Interest & Investment Income for NRIX reached as high as $6.5 million in Q1 2025 and fell as low as $211000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $3.7 million across 5 years, with a median of $3.9 million in 2024.
• On a YoY basis, Interest & Investment Income climbed as much as 2487.18% in 2022 and fell as far as 33.65% in 2022.
• Year by year, Interest & Investment Income stood at $2.0 million in 2022, then soared by 71.21% to $3.4 million in 2023, then soared by 81.05% to $6.1 million in 2024, then slipped by 20.31% to $4.9 million in 2025, then decreased by 9.77% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $4.4 million in Q2 2026, $5.3 million in Q1 2026, and $4.9 million in Q4 2025.